Nonalcoholic Fatty Liver Disease as a Contributor to Hypercoagulation and Thrombophilia in the Metabolic Syndrome

ABSTRACT

Nonalcoholic fatty liver disease (NAFLD), comprising its whole spectrum of conditions ranging from simple steatosis to steatohepatitis (nonalcoholic steatohepatitis; NASH) and cirrhosis, is the most frequent liver disease in developed countries and is now regarded as the liver manifestation of the metabolic syndrome. Several studies indicate that NAFLD, especially in its necro-inflammatory form (NASH), is associated with a systemic proinflammatory/prothrombotic state, independently of shared metabolic risk factors. This suggests that NAFLD/NASH is not simply a marker of the proinflammatory/prothrombotic state in the metabolic syndrome but is actively involved in its pathogenesis, possibly through the systemic release of proinflammatory and procoagulant factors from the steatotic liver (C-reactive protein, plasminogen activator inhibitor-1, interleukin-6, fibrinogen, and other proinflammatory cytokines). The clinical impact of NAFLD on the proinflammatory/prothrombotic risk profile deserves particular attention in view of the implications for screening and surveillance strategies in the growing number of patients with NAFLD.

KEYWORDS

Nonalcoholic fatty liver disease - blood coagulation disorders - hemostatic factors - inflammation

REFERENCES

• 1 Adams L A, Lindor K D. Nonalcoholic fatty liver disease.  Ann Epidemiol. 2007;  17 863-869
• 2 de Alwis N M, Day C P. Non-alcoholic fatty liver disease: the mist gradually clears.  J Hepatol. 2008;  48(Suppl 1) S104-S112
• 3 Clark J M. The epidemiology of nonalcoholic fatty liver disease in adults.  J Clin Gastroenterol. 2006;  40(3, Suppl 1) S5-S10
• 4 Kim H J, Kim H J, Lee K E et al.. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults.  Arch Intern Med. 2004;  164 2169-2175
• 5 Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease.  Atherosclerosis. 2007;  191 235-240
• 6 Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome.  Arterioscler Thromb Vasc Biol. 2008;  28 27-38
• 7 Tilg H, Diehl A M. Cytokines in alcoholic and nonalcoholic steatohepatitis.  N Engl J Med. 2000;  343 1467-1476
• 8 Bellentani S, Saccoccio G, Masutti F et al.. Prevalence of and risk factors for hepatic steatosis in Northern Italy.  Ann Intern Med. 2000;  132 112-117
• 9 Browning J D, Szczepaniak L S, Dobbins R et al.. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity.  Hepatology. 2004;  40 1387-1395
• 10 Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study.  Hepatology. 2005;  42 44-52
• 11 Targher G, Bertolini L, Padovani R et al.. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients.  Diabetes Care. 2007;  30 1212-1218
• 12 Marchesini G, Bugianesi E, Forlani G et al.. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.  Hepatology. 2003;  37 917-923
• 13 Eckel R H, Grundy S M, Zimmet P Z. The metabolic syndrome.  Lancet. 2005;  365 1415-1428
• 14 Bonora E. The metabolic syndrome and cardiovascular disease.  Ann Med. 2006;  38 64-80
• 15 Alessi M C, Juhan-Vague I. Metabolic syndrome, haemostasis and thrombosis.  Thromb Haemost. 2008;  99 995-1000
• 16 Lyon C J, Law R E, Hsueh W A. Minireview: adiposity, inflammation, and atherogenesis.  Endocrinology. 2003;  144 2195-2200
• 17 Nigro J, Osman N, Dart A M, Little P J. Insulin resistance and atherosclerosis.  Endocr Rev. 2006;  27 242-259
• 18 Franchini M, Targher G, Montagnana M, Lippi G. The metabolic syndrome and the risk of arterial and venous thrombosis.  Thromb Res. 2008;  122 727-735
• 19 Cigolini M, Targher G, Agostino G, Tonoli M, Muggeo M, De Sandre G. Liver steatosis and its relation to plasma haemostatic factors in apparently healthy men—role of the metabolic syndrome.  Thromb Haemost. 1996;  76 69-73
• 20 Targher G, Bertolini L, Scala L, Zoppini G, Zenari L, Falezza G. Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue.  Diabet Med. 2005;  22 1354-1358
• 21 Targher G. Relationship between high-sensitivity C-reactive protein levels and liver histology in subjects with non-alcoholic fatty liver disease.  J Hepatol. 2006;  45 879-881, author reply 881–882
• 22 Targher G, Bertolini L, Scala L et al.. Plasma PAI-1 levels are increased in patients with nonalcoholic steatohepatitis.  Diabetes Care. 2007;  30 e31-e32
• 23 Haukeland J W, Damås J K, Konopski Z et al.. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2.  J Hepatol. 2006;  44 1167-1174
• 24 Hui J M, Hodge A, Farrell G C, Kench J G, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin?.  Hepatology. 2004;  40 46-54
• 25 Musso G, Gambino R, Durazzo M et al.. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease.  Hepatology. 2005;  42 1175-1183
• 26 Yoneda M, Mawatari H, Fujita K et al.. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH.  J Gastroenterol. 2007;  42 573-582
• 27 Wieckowska A, Papouchado B G, Li Z, Lopez R, Zein N N, Feldstein A E. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis.  Am J Gastroenterol. 2008;  103 1372-1379
• 28 Yener S, Akarsu M, Demir T et al.. Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis.  J Endocrinol Invest. 2007;  30 810-819
• 29 Thuy S, Ladurner R, Volynets V et al.. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake.  J Nutr. 2008;  138 1452-1455
• 30 Jarrar M H, Baranova A, Collantes R et al.. Adipokines and cytokines in non-alcoholic fatty liver disease.  Aliment Pharmacol Ther. 2008;  27 412-421
• 31 de Larrañaga G, Wingeyer S P, Graffigna M et al.. Plasma plasminogen activator inhibitor-1 levels and nonalcoholic fatty liver in individuals with features of metabolic syndrome.  Clin Appl Thromb Hemost. 2008;  14 319-324
• 32 Ito S, Yukawa T, Uetake S, Yamauchi M. Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis.  Alcohol Clin Exp Res. 2007;  31(1, Suppl) S83-S87
• 33 Assy N, Bekirov I, Mejritsky Y, Solomon L, Szvalb S, Hussein O. Association between thrombotic risk factors and extent of fibrosis in patients with non-alcoholic fatty liver diseases.  World J Gastroenterol. 2005;  11 5834-5839
• 34 Targher G, Bertolini L, Rodella S et al.. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men.  Obesity (Silver Spring). 2008;  16 1394-1399
• 35 Kugelmas M, Hill D B, Vivian B, Marsano L, McClain C J. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E.  Hepatology. 2003;  38 413-419
• 36 Chalasani N, Deeg M A, Crabb D W. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis.  Am J Gastroenterol. 2004;  99 1497-1502
• 37 Yesilova Z, Yaman H, Oktenli C et al.. Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic fatty liver disease.  Am J Gastroenterol. 2005;  100 850-855
• 38 Konishi M, Iwasa M, Araki J et al.. Increased lipid peroxidation in patients with non-alcoholic fatty liver disease and chronic hepatitis C as measured by the plasma level of 8-isoprostane.  J Gastroenterol Hepatol. 2006;  21 1821-1825
• 39 Musso G, Gambino R, De Michieli F et al.. Nitrosative stress predicts the presence and severity of nonalcoholic fatty liver at different stages of the development of insulin resistance and metabolic syndrome: possible role of vitamin A intake.  Am J Clin Nutr. 2007;  86 661-671
• 40 Alessi M C, Bastelica D, Mavri A et al.. Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation.  Arterioscler Thromb Vasc Biol. 2003;  23 1262-1268
• 41 Wallace T M, Matthews D R. The assessment of insulin resistance in man.  Diabet Med. 2002;  19 527-534
• 42 Northup P G, Sundaram V, Fallon M B Coagulation in Liver Disease Group et al. Hypercoagulation and thrombophilia in liver disease.  J Thromb Haemost. 2008;  6 2-9
• 43 Sanyal A J, Banas C, Sargeant C et al.. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C.  Hepatology. 2006;  43 682-689
• 44 Korenblat K M, Fabbrini E, Mohammed B S, Klein S. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects.  Gastroenterology. 2008;  134 1369-1375
• 45 Day C P. From fat to inflammation.  Gastroenterology. 2006;  130 207-210
• 46 Shoelson S E, Lee J, Goldfine A B. Inflammation and insulin resistance.  J Clin Invest. 2006;  116 1793-1801
• 47 Ekstedt M, Franzén L E, Mathiesen U L et al.. Long-term follow-up of patients with NAFLD and elevated liver enzymes.  Hepatology. 2006;  44 865-873
• 48 Targher G, Bertolini L, Padovani R et al.. Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C.  J Hepatol. 2007;  46 1126-1132
• 49 Lin Z, Kumar A, SenBanerjee S et al.. Kruppel-like factor 2 (KLF2) regulates endothelial thrombotic function.  Circ Res. 2005;  96 e48-e57
• 50 Botella L M, Sánchez-Elsner T, Sanz-Rodriguez F et al.. Transcriptional activation of endoglin and transforming growth factor-beta signaling components by cooperative interaction between Sp1 and KLF6: their potential role in the response to vascular injury.  Blood. 2002;  100 4001-4010
• 51 Miele L, Beale G, Patman G et al.. The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease.  Gastroenterology. 2008;  135 282-291
• 52 Greco D, Kotronen A, Westerbacka J et al.. Gene expression in human NAFLD.  Am J Physiol Gastrointest Liver Physiol. 2008;  294 G1281-G1287
• 53 Westerbacka J, Kolak M, Kiviluoto T et al.. Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects.  Diabetes. 2007;  56 2759-2765